

Amendments to the Claims:

1-25. (Cancelled)

26. (Cancelled)

27. (Previously presented) The composition of claim 44, wherein:
the crystallized dextran microparticles comprise dextran molecules held together by
hydrogen bonds, Van Der Waals forces or ionic bonds and having substantially no covalent
bonds between dextran molecules.

28. (Previously presented) The composition of claim 44, wherein the composition
comprises an aqueous suspension of crystallized dextran microparticles and a therapeutically
effective amount of insulin.

29. (Previously presented) The composition of claim 44, wherein the composition is
located in a vessel in an amount dosed for a single oral administration to a human.

30. (Previously presented) The composition of claim 44, wherein the composition is
located in a vessel with instruction printed on the vessel or enclosed with the vessel for oral
dosage administration to a human.

31. (Previously presented) The composition of claim 44, wherein the composition
comprises a tablet comprising a pharmaceutically acceptable carrier medium, the crystallized
dextran microparticles and the therapeutically effective amount of insulin.

32. (Previously presented) The composition of claim 44, wherein the composition
comprises a capsule comprising a pharmaceutically acceptable shell, the crystallized dextran
microparticles and the therapeutically effective amount of insulin.

33. (Previously presented) The composition of claim 44, wherein:
the composition comprises a two phase composition comprising a dextran phase and a PEG phase;
the insulin is selectively partitioned in the PEG phase and the microparticles are selectively partitioned in the dextran phase; and
the composition is adapted to form a structured suspension comprising a dispersed PEG phase and a continuous dextran phase.

34. (Previously presented) A pharmaceutical composition kit, comprising:
the composition according to claim 28 located in a vessel; and
instructions for oral administration of the composition to a human in need thereof.

35. (Previously presented) A pharmaceutical kit, comprising:
a first means for orally administering a suspension of a composition according to claim 44 to a mammal to lower blood glucose of the mammal by at least 30 percent 60 minutes after administering the suspension to the mammal; and
a storage vessel containing the first means.

36. (Previously presented) A tablet comprising a pharmaceutically acceptable carrier medium and a composition according to claim 44.

37. (Previously presented) A capsule comprising a pharmaceutically acceptable shell and a composition according to claim 44.

38-40. (Canceled)

41. (Previously presented) The composition of claim 44, wherein the porous crystallized dextran microparticles have an average diameter of about 0.5 to about 5 microns.

42. (Canceled)

43. (Currently amended) A pharmaceutical composition comprising porous crystallized dextran microparticles having a porosity of at least 10% by volume and a therapeutically effective amount of insulin, wherein the insulin is selected from the group consisting of natural human insulin, recombinant human insulin, extracted bovine insulin, extracted porcine insulin, recombinant bovine insulin, recombinant porcine insulin, comprises insulin alone or in combination with an insulin analog selected from the group consisting of insulin lispro analog, humalog insulin, super insulin analog, and combinations thereof, and wherein none of the insulin is encapsulated by the porous crystallized dextran microparticles.

44. (Currently amended) A pharmaceutical composition, comprising porous crystallized dextran microparticles and a therapeutically effective amount of insulin, wherein the insulin is selected from the group consisting of natural human insulin, recombinant human insulin, extracted bovine insulin, extracted porcine insulin, recombinant bovine insulin, recombinant porcine insulin, and combinations thereof, and wherein the comprises insulin alone or in combination with an insulin analog selected from the group consisting of insulin lispro analog, humalog insulin, super insulin analog, and combinations thereof, and wherein the crystallized dextran microparticles do not act as shells with the insulin inside the shells, and none of the insulin is permeated in the pores of the insulin is encapsulated by the microparticles.

45. (Currently amended) A pharmaceutical composition, comprising porous crystallized dextran microparticles having a porosity of at least 10% by volume and a therapeutically effective amount of insulin, wherein the insulin is selected from the group consisting of natural human insulin, recombinant human insulin, extracted bovine insulin, extracted porcine insulin, recombinant bovine insulin, recombinant porcine insulin, comprises insulin alone or in combination with an insulin analog selected from the group consisting of insulin lispro analog, humalog insulin, super insulin analog, and combinations thereof, wherein the porous crystallized dextran microparticles do not act as shells with the insulin inside the

shells, and the insulin is only in the microparticles by being located in pores of the microparticles.

46. (New) The composition of claim 43, wherein the insulin is natural human insulin.
47. (New) The composition of claim 43, wherein the insulin is recombinant human insulin.
48. (New) The composition of claim 44, wherein the insulin is natural human insulin.
49. (New) The composition of claim 44, wherein the insulin is recombinant human insulin.
50. (New) The composition of claim 44, wherein the insulin is natural human insulin.
51. (New) The composition of claim 44, wherein the insulin is recombinant human insulin.